Table 3.
Serum markers and lymphocyte subsets in HIV-cHL patients according to lymphoma clinical stages.
| Population | p-Value * | |||
|---|---|---|---|---|
| Ann Arbor I-II (n = 18) | Ann Arbor III-IV (n = 26) | |||
| Serum Markers | ||||
| IL10 (pg/mL) | 0.002 | |||
| Median | 11.0 | 31.4 | ||
| IQR | 6.7–26.8 | 16.6–69.1 | ||
| n | 18 | 26 | ||
| IL6 (pg/mL) | 0.03 | |||
| Median | 5.1 | 23.9 | ||
| IQR | 2.7–30.9 | 10.8–60.4 | ||
| n | 18 | 26 | ||
| BAFF (pg/mL) | 0.01 | |||
| Median | 777.1 | 1039.6 | ||
| IQR | 471.1–1180.9 | 913.7–2338.0 | ||
| n | 18 | 26 | ||
| IgG levels (g/L) | 0.11 | |||
| Median | 12.1 | 16.2 | ||
| IQR | 10.75–16.5 | 12.8–18.8 | ||
| n | 16 | 24 | ||
| IgA levels (g/L) | 0.94 | |||
| Median | 3.0 | 2.6 | ||
| IQR | 1.9–3.7 | 1.8–3.7 | ||
| n | 16 | 24 | ||
| IgM levels (g/L) | 0.76 | |||
| Median | 0.8 | 0.7 | ||
| IQR | 0.7–1.0 | 0.4–1.2 | ||
| n | 16 | 24 | ||
| Lymphocytic subpopulations | ||||
| CD3+CD4+ T-cells | 0.50 | |||
| (cells/μL) | Median | 509 | 462 | |
| IQR | 380–581 | 349–623 | ||
| n | 18 | 26 | ||
| CD3+CD8+ T-cells | 0.71 | |||
| (cells/μL) | Median | 614 | 672 | |
| IQR | 514–891 | 394–797 | ||
| n | 18 | 26 | ||
| CD19+ | 0.30 | |||
| (cells/μL) | Median | 137 | 83 | |
| IQR | 49–222 | 42–167 | ||
| n | 16 | 25 | ||
| % CD27−IgD+ naive B-cells | 0.06 | |||
| in CD19+ | Median | 66.0 | 84 | |
| IQR | 48.6–82.2 | 67.1–92.4 | ||
| n | 13 | 21 | ||
| % CD27+IgD+ marginal zone-type | 0.10 | |||
| B-cells in CD19+ | Median | 14.4 | 4.01 | |
| IQR | 3.0–21.1 | 2.3–7.6 | ||
| n | 13 | 21 | ||
| % CD27+IgD− memory | 0.21 | |||
| B-cells in CD19+ | Median | 10.6 | 5.9 | |
| IQR | 6.8–19.9 | 2.1–5.9 | ||
| n | 13 | 21 | ||
| CD56+CD16+ NK-cells | ||||
| (cells/μL) | Median | 151 | 129 | 0.45 |
| IQR | 82–270 | 80–167 | ||
| n | 16 | 25 | ||
* p values were determined by the Wilcoxon signed-rank test. cHL: classical Hodgkin lymphoma; IQR: interquartile range; NK: natural killer.